The prescription pattern of dopamine agonists and the effect on the cardiac valvulopathy in the treatment of Parkinson’s disease
碩士 === 國立臺灣大學 === 臨床藥學研究所 === 96 === Background Recently published literatures indicated that ergot-derived dopamine receptor agonists, often used in the treatment of Parkinson''s disease, have been associated with an increased risk of valvular heart disease. Objective To evaluate the saf...
Main Authors: | Pay-Fen Lii, 李佩芬 |
---|---|
Other Authors: | Churn-Shiouh Gau |
Format: | Others |
Language: | zh-TW |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/94040330272442667809 |
Similar Items
-
The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01) -
Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease
by: Prokakis Christos, et al.
Published: (2009-11-01) -
No link to cardiac valvulopathy was seen in cabergoline treated patients
by: K Dharshini, et al.
Published: (2012-10-01) -
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
by: Shruti Khare, et al.
Published: (2017-01-01) -
Dopamine Agonist Therapy in Advanced Parkinson’s Disease
by: Heinz Reichmann
Published: (2009-05-01)